Patents by Inventor Lars Abrahmsen

Lars Abrahmsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HER2 binders
    Patent number: 12653913
    Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.
    Type: Grant
    Filed: March 8, 2023
    Date of Patent: June 16, 2026
    Assignees: GE Precision Healthcare LLC, Affibody AB
    Inventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
  • HER2 BINDERS
    Publication number: 20240139352
    Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.
    Type: Application
    Filed: March 8, 2023
    Publication date: May 2, 2024
    Inventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
  • HER2 binders
    Patent number: 11633507
    Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: April 25, 2023
    Assignees: GENERAL ELECTRIC COMPANY, AFFIBODY AB
    Inventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
  • HER2 BINDERS
    Publication number: 20210170057
    Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.
    Type: Application
    Filed: December 10, 2020
    Publication date: June 10, 2021
    Inventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
  • HER2 binders
    Patent number: 10894097
    Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionuclide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: January 19, 2021
    Assignees: GENERAL ELECTRIC COMPANY, AFFIBODY AB
    Inventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
  • POLYPEPTIDES
    Publication number: 20200199197
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29 (SEQ ID NO:1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.
    Type: Application
    Filed: January 15, 2020
    Publication date: June 25, 2020
    Inventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löfblom, Torbjörn Gräslund, Johan Seijsing
  • Polypeptides
    Patent number: 10562955
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29. The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: February 18, 2020
    Assignee: AFFIBODY AB
    Inventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löfblom, Torbjörn Gräslund, Johan Seijsing
  • POLYPEPTIDES
    Publication number: 20190375799
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for treatment or diagnosis of disease in mammals including humans.
    Type: Application
    Filed: May 8, 2019
    Publication date: December 12, 2019
    Inventors: Caroline Ekblad, Lars Abrahmsen
  • HER2 BINDERS
    Publication number: 20190262481
    Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionuclide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.
    Type: Application
    Filed: September 27, 2018
    Publication date: August 29, 2019
    Inventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
  • Polypeptides
    Patent number: 10329331
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for treatment or diagnosis of disease in mammals including humans.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: June 25, 2019
    Assignee: AFFIBODY AB
    Inventors: Caroline Ekblad, Lars Abrahmsen
  • HER2 binders
    Patent number: 10159760
    Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: December 25, 2018
    Assignee: General Electric Company
    Inventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
  • Polypeptides
    Patent number: 9975943
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2X3X4AX6X7 EIRWLPNL X16X17X18QRX21 AFIX25X26LX28X29 (SEQ ID NO: 1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: May 22, 2018
    Assignee: AFFIBODY AB
    Inventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löblom, Torbjörn Gräslund, Johan Seijsing
  • POLYPEPTIDES
    Publication number: 20180118807
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29. The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.
    Type: Application
    Filed: December 14, 2017
    Publication date: May 3, 2018
    Inventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löfblom, Torbjörn Gräslund, Johan Seijsing
  • Polypeptides
    Patent number: 9873729
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2X3X4AX6X7 EIRWLPNL X16X17X18QRX21 AFIX25X26LX28X29 (SEQ ID NO: 1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: January 23, 2018
    Assignee: AFFIBODY AB
    Inventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löblom, Torbjörn Gräslund, Johan Seijsing
  • HER2 BINDERS
    Publication number: 20160199521
    Abstract: Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.
    Type: Application
    Filed: March 29, 2016
    Publication date: July 14, 2016
    Inventors: Faisal Ahmed Syud, Brian Duh-Lan Lee, Rong Zhang, Peter Brian Iveson, Paul Schaffer, Tove Simonsson, Elin Gunneriusson, Fredrik Frejd, Lars Abrahmsen, Joachim Feldwisch, Nina Herne, Christofer Lendel
  • POLYPEPTIDES
    Publication number: 20160108095
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for treatment or diagnosis of disease in mammals including humans.
    Type: Application
    Filed: December 1, 2015
    Publication date: April 21, 2016
    Inventors: Caroline Ekblad, Lars Abrahmsen
  • POLYPEPTIDES
    Publication number: 20160031967
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2X3X4AX6X7 EIRWLPNL X16X17X18QRX21 AFIX25X26LX28X29 (SEQ ID NO: 1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.
    Type: Application
    Filed: March 17, 2014
    Publication date: February 4, 2016
    Inventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löfblom, Torbjörn Gräslund, Johan Seijsing
  • Polypeptides
    Patent number: 9211344
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for treatment or diagnosis of disease in mammals including humans.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: December 15, 2015
    Assignee: AFFIBODY AB
    Inventors: Caroline Ekblad, Lars Abrahmsen
  • Immunoglobulin G Fc region binding polypeptide
    Patent number: 9175067
    Abstract: An immunoglobulin G Fc region binding polypeptide is provided, consisting of an amino acid sequence selected from i) a variant of Protein A domain or Protein Z and ii) an amino acid sequence which has at least 95% identity thereto. Also provided are methods for producing the polypeptide, compositions comprising the polypeptide, polynucleotides encoding the polypeptide, multimers of the polypeptide, and methods of using the polypeptide.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: November 3, 2015
    Assignee: GE Healthcare Bio-Sciences AB
    Inventor: Lars Abrahmsen
  • POLYPEPTIDES
    Publication number: 20140162956
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for treatment or diagnosis of disease in mammals including humans.
    Type: Application
    Filed: July 8, 2011
    Publication date: June 12, 2014
    Inventors: Caroline Ekblad, Lars Abrahmsen